Blood Cancer

You can also try the following methods, and our professionals will serve you Customized Consultation

Cat. No.	Product Name	Field of Application
DC11726	Milademetan Featured	Milademetan (DS-3032) is a specific and orally active MDM2 inhibitor for the research of acute myeloid leukemia (AML) or solid tumors. Milademetan (DS-3032) induces G1 cell cycle arrest, senescence and apoptosis.
DC9755	eFT508(Tomivosertib) Featured	Tomivosertib (eFT-508) is a potent and selective MNK1/2 inhibitor with IC50s of 2.4 nM and 1 nM, respectively. It potentially results in decreased tumor cell proliferation and tumor growth. Tomivosertib (eFT-508) inhibits eIF4E phosphorylation and dramatically downregulates PD-L1 protein abundance.
DC5057	Enzastaurin (LY317615) Featured	Enzastaurin (LY317615) is a potent PKCβ selective inhibitor with IC50 of 6 nM, 6- to 20-fold selectivity against PKCα, PKCγ and PKCε. Phase 3.
DC7927	EPZ011989 Featured	EPZ011989 is a potent, orally-available EZH2 Inhibitor.
DC11387	Erdafitinib Featured	Erdafitinib (JNJ-42756493) is a potent and orally available FGFR family inhibitor; inhibits FGFR1-4 with IC50 values of 1.2, 2.5, 3.0 and 5.7nM, respectively.
DC8342	EW-7197 Featured	EW-7197 is a potent ALK5 inhibitor. EW-7197 showed potent in vivo anti-metastatic activity, indicating its potential for use as an anti-cancer therapy.
DC2014	Flavopiridol Featured	Flavopiridol competes with ATP to inhibit CDKs including CDK1, CDK2, CDK4 and CDK6 with IC50 of ~ 40 nM, and CDK7 with IC50 of 300 nM.
DC8780	Flavopiridol Hydrochloride Featured	Flavopiridol hydrochloride is a potent pan-cyclin-dependent kinase (CDK) inhibitor with a unique ATP-competitive mechanism.
DC8164	Gilteritinib(ASP2215) Featured	FLT3/AXL inhibitor
DC8174	Pexmetinib(ARRY-614) Featured	Pexmetinib is a potent Tie-2 and p38 MAPK dual inhibitor, with IC50s of 1 nM, 35 nM and 26 nM for Tie-2, p38α and p38β, respectively, and can be used in the research of acute myeloid leukemia.
DC10485	GDC0575（ARRY-575，RG7441） Featured	GDC0575（ARRY-575，RG7441）is a small molecule inhibitor of cell cycle checkpoint kinase 1 (Chk1), with potential chemosensitization activity.
DC5147	Molibresib (I-BET-762) Featured	GSK 525762A is a potent small molecule inhibitors that disrupt the function of the BET family of bromodomains (Brd2, Brd3, and Brd4).
DC10647	EPZ015938(pemrametostat) Featured	GSK3326595(EPZ015938) is the first-in-class protein arginine methyltransferase-5 (PRMT5) inhibitor.
DC2070	GSK690693 Featured	GSK690693 is a pan-Akt inhibitor targeting Akt1, Akt2 and Akt3 with IC50 of 2 nM, 13 nM, and 9 nM, respectively.
DC11262	IACS-010759 Featured	IACS-010759 (IACS010759) is a small molecule inhibitor of mitochondrial oxidative phosphorylation (OXPHOS), targets complex I of the mitochondrial electron transport chain.
DC3130	ICG-001 Featured	ICG-001 is a small-molecule antagonist of b-catenin/TCF-mediated transcription (IC50 = 3 uM) and specifically downregulates the expression of a subset of b-catenin/TCF-responsive genes. ICG-001 binds specifically to cyclic AMP response element-binding pro
DC4181	Imatinib mesylate Featured	Imatinib Mesylate is orally bioavailability mesylate salt of Imatinib, which is a multi-target inhibitor of v-Abl, c-Kit and PDGFR with IC50 of 0.6 μM, 0.1 μM and 0.1 μM, respectively.
DC5072	Duvelisib (IPI-145, INK1197) Featured	Duvelisib (IPI-145) is a selective inhibitor of the p110δ isoform, exhibiting IC50 values of 2.5 nM, 27.4 nM, 85 nM, and 1602 nM for p110δ, p110γ, p110β, and p110α, respectively, highlighting its specificity and potency.
DC12378	Itacitinib(INCB039110) Featured	Itacitinib is a potent and selective inhibitor of JAK1, with >20-fold selectivity for JAK1 over JAK2 and >100-fold over JAK3 and TYK2; Itacitinib is used in the research of myelofibrosis.
DC7067	KPT-330(Selinexor) Featured	KPT-330, analog of KPT-185, is an orally bioavailable selective CRM1 inhibitor.
DC8522	KW-2449 Featured	KW 2449 is a multikinase inhibitor of FLT3, ABL, ABL-T315I, and Aurora kinase.
DC7449	KW-2478 Featured	KW-2478 is a nonansamycin HSP90 inhibitor with IC50 of 3.8 nM. Phase 1/2
DC9837	Larotrectinib (LOXO-101 sulfate) Featured	LOXO-101 is a small molecule that was designed to block the ATP binding site of the TRK family of receptors, with 2 to 20 nM cellular potency against the TRKA, TRKB, and TRKC kinases.
DC8541	ORY-1001(Ladademstat) Featured	ORY-1001 dihydrochloride (RG-6016, Ladademstat) is a highly potent, selective inhibitor of lysine-specific demethylase KDM1A (LSD1) with IC50 of 18 nM, displays high selectivity for KDM1A over other FAD-containing monoamine oxidases.
DC6306	LY2157299(Galunisertib) Featured	LY2157299 is a potent TGFβ receptor I (TβRI) inhibitor with IC50 of 56 nM. Phase 2.
DC7665	Gandotinib(LY2784544) Featured	LY2784544 is a potent JAK2 inhibitor with IC50 of 3 nM, effective in JAK2V617F, 8- and 20-fold selective versus JAK1 and JAK3. Phase 2.
DC7019	LY-2874455 Featured	LY2874455 is a novel and potent FGF/FGFR inhibitor.
DC7776	LY-3039478	LY3039478 a orally bioavailable, novel small molecule Notch inhibitor with an IC50 of ~1nM in most of the tumor cell lines tested.
DC10640	LY3214996 Featured	LY3214996 is a selective and novel ERK1/2 inhibitor with IC50 of 5 nM for both enzymes in biochemical assays. It potently inhibits cellular phospho-RSK1 in BRAF and RAS mutant cancer cell lines.
DC2018	LY335979 (Zosuquidar 3HCl) Featured	LY335979 (Zosuquidar) is a potent modulator of P-glycoprotein-mediated multidrug resistance with Ki of 60 nM.

Blood Cancer

Customized Consultation X

Your information is safe with us. * Required Fields.